To assess the effect of golimumab , with or without methotrexate ( MTX ) , on serum lipids and inflammatory markers of cardiovascular disease ( CVD ) in patients with rheumatoid arthritis ( RA ) in two phase 3 , randomised , placebo-controlled trials ( GO-BEFORE and GO-FORWARD ) .
